Evidence map›Paper›PMID 36092839›Full record

ArticleTranslational andrology and urology2022

Propranolol suppresses bladder cancer by manipulating intracellular pH via NHE1.

Qian Hu, Jiali Hu, Cuiyu Chen, Yang Wang, Yu Zhang, Jielin Wan, Ouyang Jing, Hanying Yi, Shiyu Wang, Weihua Huang and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Qian HuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Jiali HuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Cuiyu ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Yang WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Yu ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Jielin WanDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Ouyang JingDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Hanying YiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Shiyu WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Weihua HuangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Jie LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Howard L McLeodDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Ran XuDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.
Yijing HeDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In recent years, a large number of clinical and epidemiological studies have revealed the anti-cancer activity of propranolol in solid tumors, though the underline mechanism is yet to be clarified. Methods: The proliferation of bladder cancer cells treated with propranolol was detected by MTS assays. Results: In this study, propranolol inhibited the expression of NHE1 and sequentially led to a decrease of intracellular pH to 5.88 in MB49 cells and 6.85 in 5637 cells, thereafter, inhibited cell viability and induced apoptosis. Furthermore, propranolol inhibited the growth of bladder cancer in mice xenograft model. Flow cytometry found that the frequency of CD8 Conclusions: These results suggested that propranolol exerted anti-proliferation and pro-apoptosis effects in bladder cancer cell by inhibiting Na

Indexed as

bladder cancerCD8+ T cellNa+/H+ exchanger (NHE1)Propranolol

Identifiers

PMID36092839
PMCPMC9459546
OpenAlexW4290702586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.